Cargando…
Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease
BACKGROUND AND AIMS: The serum free light chain assay (sFLC) is well established for aiding in the diagnosis, prognosis, and monitoring of plasma cell proliferative disorders. There are currently two commercially available sFLC immunoassays, Freelite, based on polyclonal antibody technology, and N L...
Autores principales: | Yang, Yang, Han, Xiaoyan, Zheng, Gaofeng, Cai, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482328/ https://www.ncbi.nlm.nih.gov/pubmed/31049418 http://dx.doi.org/10.1002/hsr2.113 |
Ejemplares similares
-
Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies
por: Tietsche de Moraes Hungria, Vania, et al.
Publicado: (2016) -
Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients
por: Sprangers, Ben, et al.
Publicado: (2020) -
Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma
por: Willrich, Maria Alice V., et al.
Publicado: (2022) -
Comparison of serum and urine free light chain analysis in clinical diagnosis
por: Cho, Jooyoung, et al.
Publicado: (2022) -
Analytical and clinical concordance of free light chain assay
por: Smith, Andrew, et al.
Publicado: (2018)